DESCRIPTION: There are conflicting data regarding the associations between
serum levels of OCCs (e.g., DDE) and of PCB with the risk of developing
breast cancer. The application is intended to complete a
previously-supported, case-control study to determine whether the levels of
these substances is elevated in the serum and adipose tissue of breast
cancer cases, diagnosed on Long Island, compared to controls from the same
location (benign breast disease and surgical controls). To date, 338 case
patients, 418 women with benign breast disease and 197 surgical controls
have been interviewed, and 819 adipose samples and 896 serum aliquots
collected. One fourth of these samples have been analyzed and the
preliminary results show that DDE and possibly certain PCB congeners are
associated with increased risk of breast cancer. The future plan is to
continue in order to: 1) complete assays on the remaining 3/4 of the
samples; 2) determine the lipid-adjusted serum concentrations of OCCs and
their partition between serum and adipose tissue; 3) correlate OCC levels
with age, body mass, and location in order to adjust breast cancer risk for
these confounders; 4) determine whether adjusted risk estimates differ by
estrogen receptor status of the tumors; 5) correlate OCC levels with
recurrence and mortality from breast cancer via follow-up cases; 6) study
short term (1-3 yr.) stability of serum OCC and PCB levels and the impact of
treatment on these levels; 7) estimate breast cancer risk, utilizing
different classifications for PCB congeners; and 8) determine whether
OCC-related risk of breast cancer can be correlated with degrees of atypia
of the benign breast biopsy controls, using pathologic reviews of samples
from over 400 patients.
If you are accessing this page during weekend or evening hours, the database may currently be offline for maintenance and should operational within a few hours. Otherwise, we have been notified of this error and will be addressing it immediately.
Please contact us
if this error persists.
We apologize for the inconvenience.
- The DCCPS Team.